Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Forthun, Rakel Brendsdal ^a   SenGupta, Tanima ^b   Skjeldam, Hanne Kim ^b   Lindvall, Jessica Margareta ^b,d   McCormack, Emmet ^a,c   Gjertsen, Bjørn Tore ^a,c   Nilsen, Hilde ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOPROTEIN; VALPROIC ACID;

ABCA5 GENE; ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; AGPAT4 GENE; AKT3 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAG2 GENE; CAENORHABDITIS ELEGANS; CANCER SURVIVAL; COCH GENE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SENSITIVITY; EID3 GENE; FLIPT1 GENE; GEL ELECTROPHORESIS; GENE; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IL12RB2 GENE; IMMUNOFLUORESCENCE; KCNA3 GENE; LEUKEMIA CELL LINE; MAD1 GENE; MALE; NDRG2 GENE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; RAT; SERPINF1 GENE; SMAD3 GENE; SPLEEN; WDR35 GENE; WESTERN BLOTTING;

ANIMALS; CAENORHABDITIS ELEGANS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; RATS; VALPROIC ACID;

CAENORHABDITIS ELEGANS;

EID: 84869115143     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048992     Document Type: Article

References (51)

1. Baylin SB, Jones PA, (2011) A decade of exploring the cancer epigenome- biological and translational implications. Nat Rev Cancer 11: 726-734.
2. Greer EL, Shi Y, (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13: 343-357.
3. Kooistra SM, Helin K, (2012) Molecular mechanisms and potential functions of histone demethylases. Nature reviews Molecular cell biology 13: 297-311.
4. Spiegel S, Milstien S, Grant S, (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31: 537-551.
5. Bruserud O, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, et al. (2006) Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 10: 51-68.
6. Quintas-Cardama A, Santos FP, Garcia-Manero G, (2011) Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25: 226-235.
7. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, et al. (2010) Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116: 4422-4429.
8. Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, et al. (2009) Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 8: 782-791.
9. Mazurkiewicz-Beldzinska M, Szmuda M, Matheisel A, (2010) Long-term efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents. Seizure 19: 195-197.
10. Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr, (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25: 383-397.
11. Kostrouchova M, Kostrouch Z, Kostrouchova M, (2007) Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 53: 37-49.
12. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, et al. (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222.
13. Bellos F, Mahlknecht U, (2008) Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 31: 629-633.
14. Stapnes C, Ryningen A, Hatfield K, Oyan AM, Eide GE, et al. (2007) Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol 31: 1529-1538.
15. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, et al. (2006) Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66: 8903-8911.
16. McCormack E, Haaland I, Venas G, Forthun RB, Huseby S, et al. (2012) Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 26: 910-917.
17. McDevitt MA, (2012) Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Seminars in oncology 39: 109-122.
18. Gausdal G, Gjertsen BT, McCormack E, Van Damme P, Hovland R, et al. (2008) Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood 111: 2866-2877.
19. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, et al. (2009) Functional proteomic profiling of AML predicts response and survival. Blood 113: 154-164.
20. Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, et al. (2009) Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16: 281-294.
21. Craig AL, Moser SC, Bailly AP, Gartner A, (2012) Methods for studying the DNA damage response in the Caenorhabdatis elegans germ line. Method Cell Biol 107: 321-352.
22. Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, et al. (2003) Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421: 231-237.
23. McLellan J, O'Neil N, Tarailo S, Stoepel J, Bryan J, et al. (2009) Synthetic lethal genetic interactions that decrease somatic cell proliferation in Caenorhabditis elegans identify the alternative RFC CTF18 as a candidate cancer drug target. Mol Biol Cell 20: 5306-5313.
24. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, et al. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.
25. Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, et al. (2012) RNAi screening of the kinome with cytarabine in leukemias. Blood 119: 2863-2872.
26. Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, et al. (2007) Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 35: 1527-1537.
27. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, et al. (2003) A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3: 36-44.
28. Bull VH, Fargestad EM, Strozynski M, Thiede B, (2010) Temporal proteome profiling of taxol-induced mitotic arrest and apoptosis. Electrophoresis 31: 1873-1885.
29. Schaner CE, Deshpande G, Schedl PD, Kelly WG, (2003) A conserved chromatin architecture marks and maintains the restricted germ cell lineage in worms and flies. Dev Cell 5: 747-757.
30. Hollstein M, Sidransky D, Vogelstein B, Harris CC, (1991) p53 mutations in human cancers. Science 253: 49-53.
31. Wergeland L, Sjoholt G, Haaland I, Hovland R, Bruserud O, et al. (2007) Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol Cancer 6: 33.
32. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, et al. (2007) UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449: 731-734.
33. Alexeyenko A, Sonnhammer EL, (2009) Global networks of functional coupling in eukaryotes from comprehensive data integration. Genome Res 19: 1107-1116.
34. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, et al. (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2: 2366-2382.
35. Maere S, Heymans K, Kuiper M, (2005) BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21: 3448-3449.
36. McCormack E, Skavland J, Mujic M, Bruserud O, Gjertsen BT, (2010) Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutr Cancer 62: 574-583.
37. Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, et al. (2009) A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 33: 779-787.
38. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN, (2005) Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65: 3815-3822.
39. Nie D, Huang K, Yin S, Li Y, Xie S, et al. (2012) Synergistic/additive interaction of valproic acid with bortezomib on the proliferation and apoptosis of acute myeloid leukemia cells. Leukemia Lymphoma.
40. Mielnicki LM, Asch HL, Asch BB, (2001) Genes, chromatin, and breast cancer: an epigenetic tale. J Mammary Gland Biol 6: 169-182.
41. Morita K, Shimizu M, Shibuya H, Ueno N, (2001) A DAF-1-binding protein BRA-1 is a negative regulator of DAF-7 TGF-beta signaling. Proc Natl Acad Sci U S A 98: 6284-6288.
42. Corpet A, Almouzni G, (2009) A histone code for the DNA damage response in mammalian cells? EMBO J 28: 1828-1830.
43. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, et al. (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521-523.
44. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, et al. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145: 788-800.
45. Wang JK, Tsai MC, Poulin G, Adler AS, Chen S, et al. (2010) The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev 24: 327-332.
46. Hong S, Cho YW, Yu LR, Yu H, Veenstra TD, et al. (2007) Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci U S A 104: 18439-18444.
47. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
48. Lin HK, Bergmann S, Pandolfi PP, (2005) Deregulated TGF-beta signaling in leukemogenesis. Oncogene 24: 5693-5700.
49. Band AM, Bjorklund M, Laiho M, (2009) The phosphatidylinositol 3-kinase/Akt pathway regulates transforming growth factor-{beta} signaling by destabilizing ski and inducing Smad7. J Biol Chem 284: 35441-35449.
50. Marina O, Hainz U, Biernacki MA, Zhang W, Cai A, et al. (2010) Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res 70: 1344-1355.
51. Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, et al. (2007) Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol 107: 266-273.